Financial Performance - Lionsgate Studios Corp. reported a quarterly loss of $0.20 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.14, representing an earnings surprise of -42.86% [1] - The company posted revenues of $475.1 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 21%, and a significant decline from year-ago revenues of $823.7 million [2] - Over the last four quarters, the company has surpassed consensus EPS estimates only once [2] Stock Performance - Shares of Lionsgate Studios Corp. have declined approximately 11.3% since the beginning of the year, contrasting with the S&P 500's gain of 15.6% [3] - The current Zacks Rank for the stock is 4 (Sell), indicating expectations of underperformance in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.06 on revenues of $714.91 million, while for the current fiscal year, the estimate is -$0.13 on revenues of $2.8 billion [7] - The trend of estimate revisions for Lionsgate Studios Corp. was unfavorable prior to the earnings release, which may impact future stock movements [5][6] Industry Context - The Media Conglomerates industry, to which Lionsgate Studios Corp. belongs, is currently ranked in the bottom 29% of over 250 Zacks industries, suggesting a challenging environment for the stock [8]

Core Viewpoint - InfuSystems Holdings, Inc. (INFU) has seen a 1.8% increase in share price over the past four weeks, closing at $10, with analysts suggesting a potential upside of 40% based on a mean price target of $14 [1] Price Targets - The average price target consists of five estimates ranging from a low of $12.00 to a high of $15.00, with a standard deviation of $1.41, indicating a potential increase of 20% to 50% from the current price level [2] - A low standard deviation suggests a strong agreement among analysts regarding the price targets, which can be a positive indicator for investors [2][9] Analyst Sentiment - Analysts have shown increasing optimism about INFU's earnings prospects, as evidenced by a positive trend in earnings estimate revisions, which historically correlates with stock price movements [4][11] - The Zacks Consensus Estimate for the current year has risen by 13.7% over the past month, with no negative revisions, indicating a favorable outlook for the company [12] Zacks Rank - INFU holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, further supporting the potential for stock price appreciation [13] Conclusion on Price Movement - While the consensus price target may not be entirely reliable, the direction indicated by the price movement appears to be a useful guide for potential investment decisions [14]

Core Viewpoint - Arcutis Biotherapeutics, Inc. (ARQT) shows significant potential for upside, with a current stock price of $24.01 and a mean price target of $30.38, indicating a 26.5% upside potential [1]. Price Targets - The average of eight short-term price targets ranges from a low of $29.00 to a high of $32.00, with a standard deviation of $1.19, suggesting a relatively high agreement among analysts [2]. - The lowest estimate indicates a potential increase of 20.8%, while the most optimistic estimate points to a 33.3% upside [2]. Analyst Sentiment - Analysts are increasingly optimistic about ARQT's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has historically correlated with stock price movements [4][11]. - Over the last 30 days, three earnings estimates have been revised higher, leading to a 46.5% increase in the Zacks Consensus Estimate for the current year [12]. Zacks Rank - ARQT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, which further supports the stock's potential upside [13]. Conclusion on Price Targets - While the consensus price target may not be a reliable indicator of the magnitude of ARQT's potential gains, the direction implied by these targets appears to be a useful guide for further research [14].

Core Viewpoint - Creative Medical Technology Holdings, Inc. (CELZ) has experienced a bearish trend, losing 49% in stock price over the past week, but the formation of a hammer chart pattern suggests a potential trend reversal as buying interest may be emerging [1][2]. Technical Analysis - The hammer chart pattern indicates a possible bottoming out, with reduced selling pressure, suggesting that bulls may be gaining control [2][5]. - A hammer pattern forms when there is a small candle body with a long lower wick, typically occurring during a downtrend, indicating a potential reversal if it appears at the bottom of the trend [4][5]. - The effectiveness of the hammer pattern is enhanced when used alongside other bullish indicators, as its strength is dependent on its placement on the chart [6]. Fundamental Analysis - There has been a notable upward trend in earnings estimate revisions for CELZ, which is a bullish indicator, as it often correlates with price appreciation [7]. - Over the last 30 days, the consensus EPS estimate for CELZ has increased by 32.3%, indicating strong agreement among analysts that the company will report better earnings than previously predicted [8]. - CELZ holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [9][10].

Core Viewpoint - Columbus McKinnon (CMCO) shows significant upside potential with a mean price target of $31, indicating a 104.1% upside from the current price of $15.19 [1] Price Targets and Estimates - The average price target for CMCO ranges from a low of $15.00 to a high of $50.00, with a standard deviation of $17.69, suggesting variability in analyst estimates [2] - The lowest estimate indicates a potential decline of 1.3%, while the highest suggests a 229.2% upside [2] - Analysts' consensus on price targets should be approached with caution, as their reliability has been questioned [3][7] Earnings Estimates and Analyst Agreement - Strong agreement among analysts regarding CMCO's earnings prospects supports the expectation of stock upside, as indicated by positive earnings estimate revisions [4][11] - The Zacks Consensus Estimate for the current year has increased by 1.6% over the past month, with no negative revisions [12] - CMCO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Conclusion on Price Movement - While the consensus price target may not be a reliable indicator of potential gains, the direction implied by these targets appears to be a useful guide for further research [14]

Core Viewpoint - Tree.com (TREE) shares have increased by 5.1% in the last four weeks, closing at $62.02, with a potential upside of 31.1% based on Wall Street analysts' mean price target of $81.33 [1][11]. Price Targets - The average price target consists of six estimates ranging from a low of $72.00 to a high of $85.00, with a standard deviation of $4.93, indicating a relatively tight clustering of estimates [2][9]. - The lowest estimate suggests a 16.1% increase from the current price, while the highest indicates a 37.1% upside [2]. Analyst Sentiment - Analysts show strong agreement in revising earnings estimates higher, which historically correlates with stock price movements [4][11]. - The Zacks Consensus Estimate for the current year has risen by 29.7% over the past month, with three estimates increasing and no negative revisions [12]. Zacks Rank - TREE holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential upside [13]. Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, as empirical research indicates they rarely predict actual stock price movements accurately [7][10]. - Analysts may set optimistic price targets due to business incentives, which can inflate expectations [8][9].

分组1 - Select Medical (SEM) shares have increased by 2.5% over the past four weeks, closing at $13.37, with a mean price target of $18.17 indicating a potential upside of 35.9% [1] - The mean estimate consists of six short-term price targets with a standard deviation of $2.64, where the lowest estimate is $14.00 (4.7% increase) and the highest is $21.00 (57.1% increase) [2] - Analysts show strong agreement in revising SEM's earnings estimates higher, which correlates with potential stock price increases [11][12] 分组2 - The Zacks Consensus Estimate for SEM has risen by 4.5% over the past month, with two estimates increasing and no negative revisions [12] - SEM holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can indicate the direction of price movement [14]

Group 1: Stock Performance and Price Targets - Life Time Group Holdings, Inc. (LTH) shares have increased by 0.5% over the past four weeks, closing at $26.18, with a mean price target of $39.23 indicating a potential upside of 49.9% [1] - The average of 13 short-term price targets ranges from a low of $28.00 to a high of $48.00, with a standard deviation of $5.53, suggesting a 7% increase from the current price at the lowest estimate and an 83.4% upside at the highest [2] Group 2: Analyst Consensus and Earnings Estimates - There is strong agreement among analysts regarding LTH's ability to report better earnings than previously predicted, which supports the view of potential upside [4] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 0.1%, with two estimates moving higher and no negative revisions [12] - LTH currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Group 3: Caution on Price Targets - Solely relying on consensus price targets for investment decisions may not be wise, as analysts' ability to set unbiased targets has been questioned [3] - Price targets set by analysts often reflect overly optimistic views due to business incentives, which can lead to inflated estimates [8] - While a tight clustering of price targets indicates agreement among analysts, it does not guarantee that the stock will reach the average target [9]

Group 1: Earnings Performance - Bentley Systems reported quarterly earnings of $0.27 per share, matching the Zacks Consensus Estimate, and an increase from $0.24 per share a year ago [1] - The company posted revenues of $375.55 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 2.59% and up from $335.17 million year-over-year [2] - Over the last four quarters, Bentley Systems has surpassed consensus EPS estimates two times and revenue estimates three times [2][1] Group 2: Stock Performance and Outlook - Bentley Systems shares have increased approximately 4.8% since the beginning of the year, while the S&P 500 has gained 15.1% [3] - The company's earnings outlook will be crucial for future stock movements, with current consensus EPS estimates at $0.28 for the coming quarter and $1.21 for the current fiscal year [7] - The estimate revisions trend for Bentley Systems was unfavorable ahead of the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Group 3: Industry Context - The Internet - Software industry, to which Bentley Systems belongs, is currently in the top 34% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Viewpoint - Toro (TTC) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][2]. Earnings Estimates and Stock Price Movement - The Zacks rating system emphasizes the importance of changing earnings estimates in determining short-term stock price movements, making it a valuable tool for investors [2][3]. - The correlation between earnings estimate revisions and stock price movements is strong, with institutional investors using these estimates to assess fair value, leading to significant trading activity that affects stock prices [3]. Toro's Earnings Outlook - For the fiscal year ending October 2025, Toro is expected to earn $4.15 per share, which remains unchanged from the previous year, but analysts have raised their estimates by 0.9% over the past three months [7]. Zacks Rank System - The Zacks Rank system categorizes stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks yielding an average annual return of +25% since 1988 [6]. - The upgrade of Toro to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [9].